Zolgensma (onasemnogene abeparvovec-xioi) (Onasemnogene Abeparvovec KIT)

Zolgensma (onasemnogene abeparvovec) is a gene therapy medication developed by Novartis Gene Therapy for the treatment of spinal muscular atrophy (SMA). It received FDA approval as a breakthrough therapy and orphan drug designation for SMA type 1 and pre-symptomatic SMA. This innovative cell and gene therapy represents a paradigm shift in neuromuscular disease treatment.

Pack Size

1 KIT in 1 CARTON (71894-120-02) * 1 mL in 1 POUCH * 8.3 mL in 1 VIAL (71894-115-01)

Manufacturer / TM Owner

Novartis Gene Therapy

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Zolgensma is indicated for the treatment of spinal muscular atrophy (SMA) type 1 and pre-symptomatic SMA in pediatric patients. SMA is a rare, inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to progressive muscle weakness and atrophy. Zolgensma works by delivering a functional copy of the human SMN gene via an adeno-associated viral (AAV) vector, enabling motor neurons to produce survival motor neuron (SMN) protein. This mechanism restores motor neuron function and halts disease progression. The drug is administered as a single intravenous infusion, making it a one-time treatment option. It is designed for infants and young children, with the goal of preventing or significantly delaying symptom onset and improving motor function and survival outcomes in this devastating pediatric condition.

Side Effects

Common adverse events associated with Zolgensma include elevated liver transaminases (ALT/AST), thrombocytopenia, and elevated creatinine. Serious adverse events include hepatotoxicity, thrombotic microangiopathy, and acute kidney injury. Patients require comprehensive baseline and post-infusion monitoring including liver function tests, platelet counts, and renal function. Regular clinical assessments and motor function evaluations are essential. Immunosuppressive therapy may be administered to mitigate immune responses. Close monitoring for signs of hepatic dysfunction, bleeding, or renal complications is critical during the first months following infusion.

Precautions & Warnings

Zolgensma is contraindicated in patients with active hepatic disease or severe hepatic impairment. Caution is advised in patients with pre-existing liver dysfunction, thrombocytopenia, or renal impairment. The drug is not recommended during pregnancy due to potential risks to the fetus; reproductive potential should be considered. Pediatric use is the primary indication; safety and efficacy in adults have not been established. Patients with active infections or immunocompromised states require careful evaluation. Pre-existing anti-AAV antibodies may reduce efficacy. Baseline comprehensive metabolic panel, liver function tests, and coagulation studies are mandatory before administration.

Avoid Interactions

Limited drug-drug interaction data are available for Zolgensma due to its gene therapy mechanism. Corticosteroids and other immunosuppressive agents may be co-administered as part of the treatment protocol to reduce immune responses. Avoid concurrent administration of live vaccines. NSAIDs and anticoagulants should be used cautiously due to thrombocytopenia risk. Hepatotoxic medications should be avoided or used with extreme caution. Patients should inform healthcare providers of all concurrent medications, supplements, and recent vaccinations prior to Zolgensma administration.

Frequently Asked Questions

Zolgensma is used to treat spinal muscular atrophy (SMA) type 1 and pre-symptomatic SMA in pediatric patients. It is a gene therapy that delivers a functional SMN gene to restore motor neuron function and prevent or delay disease progression. This one-time intravenous infusion can significantly improve motor function and survival outcomes in affected children.

Zolgensma is administered as a single intravenous infusion, typically in a hospital or specialized treatment center. The infusion is carefully monitored by healthcare professionals. Prior to administration, patients receive immunosuppressive therapy to reduce potential immune responses to the viral vector.

Common side effects include elevated liver enzymes (ALT/AST), low platelet counts (thrombocytopenia), and elevated creatinine levels. Most adverse events are manageable with appropriate monitoring and supportive care. Serious complications such as hepatotoxicity or kidney injury, though rare, require immediate medical attention.

Zolgensma is manufactured by Novartis Gene Therapy, a division of Novartis Pharmaceuticals. Novartis is a leading global pharmaceutical company specializing in innovative therapies including gene and cell therapies.

Yes, Zolgensma received orphan drug designation from the FDA for the treatment of spinal muscular atrophy. This designation recognizes its development for a rare disease affecting a small patient population. Orphan drug status provides regulatory incentives and expedited review pathways to bring life-saving therapies to patients with rare diseases.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.